SCHEMBL25811497

SCHEMBL25811497

Cc1[nH]c2ccc(C(=O)NCCN3CCN(C)CC3)cc2c1C

nearest known ligand 0.74

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 1/20 0.73
MAPT P10636 8/20 0.65
SMN1; SMN2 Q16637 1/20 0.65
LMNA P02545 2/20 0.64
HTT P42858 1/20 0.64
HDAC2 Q92769 1/20 0.57
HDAC8 Q9BY41 1/20 0.57
HDAC6 Q9UBN7 1/20 0.57
RAD52 P43351 1/20 0.56
KDM4E B2RXH2 2/20 0.56
ALDH1A1 P00352 2/20 0.56
L3MBTL1 Q9Y468 2/20 0.56
GAA P10253 1/20 0.55
HPGD P15428 1/20 0.55
HSD17B10 Q99714 1/20 0.55
RAB9A P51151 3/20 0.55
POLB P06746 1/20 0.54
NPC1 O15118 2/20 0.53
PARP1 P09874 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30312303 0.92 KMT2A (0.82) KMT2AMAPTSMN1; SMN2LMNAHTT
SCHEMBL25811263 0.92 KMT2A (0.85) KMT2AMAPTSMN1; SMN2LMNAHTT
SCHEMBL25811246 0.92 KMT2A (0.82) KMT2AMAPTSMN1; SMN2LMNAHTT
SCHEMBL25811307 0.91 KMT2A (0.88) KMT2AMAPTSMN1; SMN2LMNAHTT
SCHEMBL25811210 0.89 KMT2A (0.70) KMT2AMAPTSMN1; SMN2LMNAHTT
SCHEMBL25811229 0.88 KMT2A (0.58) KMT2AMAPTSMN1; SMN2LMNAHTT
SCHEMBL25811242 0.88 TLR9 (0.60) KMT2AMAPTSMN1; SMN2LMNAHTT
SCHEMBL25811277 0.81 TP53 (0.69) KMT2AMAPTSMN1; SMN2LMNAHDAC2
SCHEMBL25811273 0.80 KMT2A (0.64) KMT2AMAPTSMN1; SMN2LMNAHTT
SCHEMBL25811223 0.80 KMT2A (0.64) KMT2AMAPTPARP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230218573-A1 INDOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES GALYAN BIO INC (US) 2023-07-13 US disclosed
US-20230218573-A1 INDOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES GALYAN BIO INC (US) 2023-07-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230218573-A1 INDOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES HTT, HYPK, PARK7 KMT2A 981/4885MAPT 18/4885SMN1; SMN2 156/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.